



Renowned Proteomic Researchers to Present Quantum-Si Data at World HUPO 2024

October 10, 2024

BRANFORD, Conn.--(BUSINESS WIRE)--Oct. 10, 2024-- [Quantum-Si Incorporated](#) (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced its participation at the Human Proteome Organization (HUPO) World Congress 2024 in Dresden, Germany. As a leader in Next-Generation Protein Sequencing™ (NGPS), Quantum-Si will be joined by prominent researchers to present data showcasing advancements in proteomic analysis.

Quantum-Si's latest developments, featuring data from Platinum®[®], the world's first and only NGS instrument on the market, will be highlighted in two key poster sessions:

Poster Presentations:

- Quantum-Si's Next-Generation Protein Sequencer™ Enables Protein Detection and Peptide Characterization from Biological Samples
 - Presented by John Kudolo, PhD, Quantum-Si
 - Poster ID: P-III-0753 | Date: Wednesday, October 23
- Integrated Sequencing of Single Transcript and Protein Molecules Discerns Alternatively Spliced Tropomyosin Proteoforms
 - Presented by Gloria Sheynkman, PhD, University of Virginia
 - Poster ID: P-III-0758 | Date: Wednesday, October 23

In addition to the poster presentations, Quantum-Si will host a breakfast talk on Tuesday, October 22, titled "*Joining Forces: Next-Generation Protein Sequencing™ and Top-Down Mass Spectrometry Combine to Enhance Proteoform Analysis*." The session will be led by Dr. Meredith Carpenter, Quantum-Si's Head of Scientific Affairs, and Dr. Neil Kelleher from Northwestern University.

These presentations will showcase new data demonstrating how Platinum addresses applications including detection of protein variants and post-translational modifications, protein barcoding, and characterization of proteoforms in tandem with top-down mass spectrometry.

"We are honored to have such accomplished researchers presenting data from Platinum at HUPO 2024," said Jeff Hawkins, Chief Executive Officer of Quantum-Si. "The ability to detect and characterize proteins and peptides with such depth and precision is a significant step forward for proteomic research. We continue to believe our technology has the potential to transform how scientists approach biological discovery."

For more information about Quantum-Si's innovative solutions and to meet the team at World HUPO 2024, attendees can visit booth #24.

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at [quantum-si.com](#) or follow us on [LinkedIn](#) or [X](#).

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company's ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company's commercialized Platinum™ protein sequencing instrument and kits and the Company's other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K, and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any

change in events, conditions, or circumstances on which any such statement is based.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20241010243916/en/): <https://www.businesswire.com/news/home/20241010243916/en/>

Investor Contact

Doug Farrell, VP, Investor Relations

ir@quantum-si.com

Media Contact

Katherine Atkinson, SVP, Commercial Marketing

media@quantum-si.com

Source: Quantum-Si Incorporated